View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNext Science 将来の成長Future 基準チェック /06現在、 Next Scienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 11Next Science Limited to Report Q1, 2025 Results on Apr 24, 2025Next Science Limited announced that they will report Q1, 2025 results on Apr 24, 2025お知らせ • Mar 11Next Science Limited, Annual General Meeting, May 09, 2025Next Science Limited, Annual General Meeting, May 09, 2025.お知らせ • Feb 07Next Science Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Next Science Limited announced that they will report fiscal year 2024 results on Feb 28, 2025お知らせ • Jan 20Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025Next Science Limited announced that they will report Q4, 2024 results on Jan 23, 2025お知らせ • Jan 08Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former EmployeeNext Science Limited announced that a former employee, Michael Morello has filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging breaches of fiduciary duties and mismanagement against several employees. Mr. Morello was VP, Wound Care Sales at Next Science LLC until December 2023. In May 2024, Next Science LLC commenced litigation against Mr. Morello and several former employees for breach of post-employment restraints. Mr. Morello's complaint makes several claims including that Next Science's XBIO technology has not been approved by the FDA as a biofilm eradication process and that the Company did not take adequate measures to address safety concerns about the use of its surgical solution XPERIENCETM in breast implant procedures. The Company confirms that the products it sells are safe, effective, approved by the FDA (the US healthcare regulatory authority) and promoted within their FDA approved intended use. The Board is concerned that the Complaint has not been brought in good faith due to the fact that Mr. Morello has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged. Next Science has, in consultation with its insurers, engaged US attorneys in relation to both proceedings and the Company and Next Science LLC will continue to pursue the Non- Compete Action against Mr. Morello and several former employees for the breach of post- employment restraints. Next Science will provide further updates as and when there is material progress in these USA civil proceedings.お知らせ • Oct 16Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024Next Science Limited announced that they will report Q3, 2024 results on Oct 22, 2024お知らせ • Jul 26Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024Next Science Limited announced that they will report first half, 2024 results on Aug 30, 2024お知らせ • Jul 10Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024Next Science Limited announced that they will report Q2, 2024 results on Jul 25, 2024お知らせ • Apr 23Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024Next Science Limited announced that they will report Q1, 2024 results on Apr 24, 2024お知らせ • Mar 04Next Science Limited, Annual General Meeting, May 03, 2024Next Science Limited, Annual General Meeting, May 03, 2024, at 10:01 E. Australia Standard Time.お知らせ • Feb 16Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024Next Science Limited announced that they will report fiscal year 2023 results on Feb 28, 2024お知らせ • Nov 01Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,571,429 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,851,024 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,244,504 Price\Range: AUD 0.42 Transaction Features: Reserved Share Offering; Subsequent Direct Listingお知らせ • Oct 24Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive DirectorNext Science Limited announced the appointment of Ms. Katherine Ostin as an independent Non Executive Director of the Company and Chair of the Board’s Audit and Risk Committee with effect from 24 October 2023. Ms. Ostin is an experienced non-executive director and audit and risk committee chair. Ms. Ostin’s appointment strengthens the Board’s skills in a number of key areas including finance and accounting, audit, risk, governance, strategy and business development. Ms. Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in the aged care and healthcare sectors, having established and led KPMG’s New South Wales Health, Ageing and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms. Ostin worked in Australia, the US, Asia, and the UK. Ms. Ostin currently serves as a Non-Executive Director of 3P Learning Limited, dusk Group Limited, Capral Limited and Alex Corporation Limited. She holds a Bachelor of Commerce (Accounting and Finance) from the University of New South Wales and is a Fellow of the Financial Services Institute of Australasia. Ms. Ostin is also a graduate of the Australian Institute of Company Directors (AICD).お知らせ • Aug 23Next Science Limited Announces Board ChangesNext Science Limited announced the appointment of Ms. Aileen Stockburger as Chair of the Next Science Board of Directors and the appointment of a long standing advisor to the Company, Mr. Grant Hummel, as an independent Non-Executive Director, effective 23 August 2023, further strengthening the skills of the Board in a number of key areas including strategy, financial acumen, legal and governance. The timing of the Board changes has been brought about following the retirement of Mr. Mark Compton AM as Chair of the Company. Mr. Compton’s retirement from the Board follows two recent close family bereavements and his need to take some personal time. Aileen Stockburger has been an independent Non-Executive Director of the Company since 2018, having joined ahead of the Company’s admission to ASX. Ms Stockburger was most recently re-elected by shareholders at the Company’s 2023 Annual General Meeting. Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Ms Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania and is a Certified Public Accountant (CPA USA). She is a Non-Executive Director of Microbot Medical and two private equity companies - Orchid Orthopaedic Solutions and Materna Medical. Ms Stockburger is also a graduate of the Australian Institute of Company Directors (AICD). Grant Hummel was part of the Company’s initial public offering (IPO) and ASX listing deal team in 2019. Mr. Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr. Hummel has been a non-executive director of GLG Corp. Ltd. since 2018 and serves as the Chair of GLG’s Nomination and Remuneration Committee and as a member of GLG’s Audit and Risk Committee. Mr. Hummel holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. He also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan). Mr. Hummel has also been appointed as a member of the Board's Audit and Risk Committee and People, Culture and Remuneration Committee. Ms. Stockburger will remain as Chair of the Board's Audit and Risk Committee and independent Non-Executive Director, Mr. DanSpira, will continue to Chair the Board's People, Culture and Remuneration Committee. The Board will continue its ongoing search for at least one new independent non-executive director who may be US based.お知らせ • Jun 30+ 1 more updateNext Science Limited Appoints Marc Zimmerman as Chief Financial OfficerThe Board of Next Science Limited appointment and commencement of Marc Zimmerman as Chief Financial Officer.お知らせ • Jun 29Next Science Limited Commercialising Its Proprietary Xbiotm Suite of ProductsNext Science Limited announced commercialising its proprietary XBIOTM suite of products to reduce the impact of biofilm-based infections in human health, provide the following update. In advance of the forthcoming Appendix 4C and quarterly activity report, Next Science notes continuing improvement in the performance of the business across the quarter-to-date. Next Science advises, that with a few days left in the month, unaudited product sales for 2QFY23 are expected to be above USD 5.6 million. This compares with reported product sales of USD 4.4 million in 1QFY23. As the period for 1HFY23 is about to close, it is clear, that Next Science is on track to substantially exceed product sales in 1HFY22 (USD 5.2 million) and 2HFY22 (USD 6.1 million). This is due to the increased investment in sales and marketing that will continue during the establishment phase of the direct sales model for key products.お知らせ • Jun 17+ 1 more updateNext Science Limited Announces Executive ChangesNext Science Limited announced the appointment of Harry Thomas Hall, IV (commonly known as I.V.) as its new Managing Director and Chief Executive Officer (CEO). I.V. will commence as CEO on 10 July 2023. To ensure a comprehensive and smooth handover, current CEO, Judith Mitchell, will remain with the company until the end of July. New CEO - Harry Thomas Hall, IV (I.V.): Over the course of 28 years in the global medical device industry, I.V. has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. I.V. joined DePuy Synthes, a subsidiary of Johnson and Johnson in 1997 where he held senior roles including: Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. I.V. was most recently a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes and completed the launch of the first surgical robot developed by JNJ /DePuy Synthes. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V. was responsible for a global portfolio and execution strategy for a USD 3.2 billion platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, I.V. created and sustained personal relationships with well over one hundred key opinion leaders worldwide. I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School. I.V. will be relocating from Pennsylvania to be permanently based in Jacksonville, Florida.お知らせ • Feb 10+ 4 more updatesNext Science Limited to Report Q2, 2023 Results on Jul 31, 2023Next Science Limited announced that they will report Q2, 2023 results on Jul 31, 2023 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Next Science は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:NXSC.F - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202522-9-6-6N/A3/31/202522-10-7-7N/A12/31/202423-11-9-8N/A9/30/202423-12-11-10N/A6/30/202423-14-13-12N/A3/31/202423-15-14-14N/A12/31/202322-16-16-15N/A9/30/202319-15-15-14N/A6/30/202316-15-14-13N/A3/31/202314-14-13-13N/A12/31/202212-13-12-12N/A9/30/202211-12-12-12N/A6/30/202210-12-12-11N/A3/31/202210-11-10-10N/A12/31/20219-9-9-8N/A9/30/20218-9-10-9N/A6/30/20216-9-11-10N/A3/31/20215-11-12-11N/A12/31/20203-12-13-12N/A9/30/20203-12-12-11N/A6/30/20203-13-11-10N/A3/31/20203-13-13-11N/A12/31/20194-14-14-12N/A9/30/20194-15-14-13N/A6/30/20194-16-15-14N/A3/31/20194-15N/A-13N/A12/31/20183-14N/A-12N/A12/31/20174-2N/AN/AN/A12/31/20161-3N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NXSC.Fの予測収益成長が 貯蓄率 ( 3.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NXSC.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NXSC.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NXSC.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NXSC.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NXSC.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/19 02:06終値2026/02/17 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Next Science Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 11Next Science Limited to Report Q1, 2025 Results on Apr 24, 2025Next Science Limited announced that they will report Q1, 2025 results on Apr 24, 2025
お知らせ • Mar 11Next Science Limited, Annual General Meeting, May 09, 2025Next Science Limited, Annual General Meeting, May 09, 2025.
お知らせ • Feb 07Next Science Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Next Science Limited announced that they will report fiscal year 2024 results on Feb 28, 2025
お知らせ • Jan 20Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025Next Science Limited announced that they will report Q4, 2024 results on Jan 23, 2025
お知らせ • Jan 08Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former EmployeeNext Science Limited announced that a former employee, Michael Morello has filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging breaches of fiduciary duties and mismanagement against several employees. Mr. Morello was VP, Wound Care Sales at Next Science LLC until December 2023. In May 2024, Next Science LLC commenced litigation against Mr. Morello and several former employees for breach of post-employment restraints. Mr. Morello's complaint makes several claims including that Next Science's XBIO technology has not been approved by the FDA as a biofilm eradication process and that the Company did not take adequate measures to address safety concerns about the use of its surgical solution XPERIENCETM in breast implant procedures. The Company confirms that the products it sells are safe, effective, approved by the FDA (the US healthcare regulatory authority) and promoted within their FDA approved intended use. The Board is concerned that the Complaint has not been brought in good faith due to the fact that Mr. Morello has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged. Next Science has, in consultation with its insurers, engaged US attorneys in relation to both proceedings and the Company and Next Science LLC will continue to pursue the Non- Compete Action against Mr. Morello and several former employees for the breach of post- employment restraints. Next Science will provide further updates as and when there is material progress in these USA civil proceedings.
お知らせ • Oct 16Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024Next Science Limited announced that they will report Q3, 2024 results on Oct 22, 2024
お知らせ • Jul 26Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024Next Science Limited announced that they will report first half, 2024 results on Aug 30, 2024
お知らせ • Jul 10Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024Next Science Limited announced that they will report Q2, 2024 results on Jul 25, 2024
お知らせ • Apr 23Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024Next Science Limited announced that they will report Q1, 2024 results on Apr 24, 2024
お知らせ • Mar 04Next Science Limited, Annual General Meeting, May 03, 2024Next Science Limited, Annual General Meeting, May 03, 2024, at 10:01 E. Australia Standard Time.
お知らせ • Feb 16Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024Next Science Limited announced that they will report fiscal year 2023 results on Feb 28, 2024
お知らせ • Nov 01Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,571,429 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,851,024 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,244,504 Price\Range: AUD 0.42 Transaction Features: Reserved Share Offering; Subsequent Direct Listing
お知らせ • Oct 24Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive DirectorNext Science Limited announced the appointment of Ms. Katherine Ostin as an independent Non Executive Director of the Company and Chair of the Board’s Audit and Risk Committee with effect from 24 October 2023. Ms. Ostin is an experienced non-executive director and audit and risk committee chair. Ms. Ostin’s appointment strengthens the Board’s skills in a number of key areas including finance and accounting, audit, risk, governance, strategy and business development. Ms. Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in the aged care and healthcare sectors, having established and led KPMG’s New South Wales Health, Ageing and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms. Ostin worked in Australia, the US, Asia, and the UK. Ms. Ostin currently serves as a Non-Executive Director of 3P Learning Limited, dusk Group Limited, Capral Limited and Alex Corporation Limited. She holds a Bachelor of Commerce (Accounting and Finance) from the University of New South Wales and is a Fellow of the Financial Services Institute of Australasia. Ms. Ostin is also a graduate of the Australian Institute of Company Directors (AICD).
お知らせ • Aug 23Next Science Limited Announces Board ChangesNext Science Limited announced the appointment of Ms. Aileen Stockburger as Chair of the Next Science Board of Directors and the appointment of a long standing advisor to the Company, Mr. Grant Hummel, as an independent Non-Executive Director, effective 23 August 2023, further strengthening the skills of the Board in a number of key areas including strategy, financial acumen, legal and governance. The timing of the Board changes has been brought about following the retirement of Mr. Mark Compton AM as Chair of the Company. Mr. Compton’s retirement from the Board follows two recent close family bereavements and his need to take some personal time. Aileen Stockburger has been an independent Non-Executive Director of the Company since 2018, having joined ahead of the Company’s admission to ASX. Ms Stockburger was most recently re-elected by shareholders at the Company’s 2023 Annual General Meeting. Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Ms Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania and is a Certified Public Accountant (CPA USA). She is a Non-Executive Director of Microbot Medical and two private equity companies - Orchid Orthopaedic Solutions and Materna Medical. Ms Stockburger is also a graduate of the Australian Institute of Company Directors (AICD). Grant Hummel was part of the Company’s initial public offering (IPO) and ASX listing deal team in 2019. Mr. Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr. Hummel has been a non-executive director of GLG Corp. Ltd. since 2018 and serves as the Chair of GLG’s Nomination and Remuneration Committee and as a member of GLG’s Audit and Risk Committee. Mr. Hummel holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. He also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan). Mr. Hummel has also been appointed as a member of the Board's Audit and Risk Committee and People, Culture and Remuneration Committee. Ms. Stockburger will remain as Chair of the Board's Audit and Risk Committee and independent Non-Executive Director, Mr. DanSpira, will continue to Chair the Board's People, Culture and Remuneration Committee. The Board will continue its ongoing search for at least one new independent non-executive director who may be US based.
お知らせ • Jun 30+ 1 more updateNext Science Limited Appoints Marc Zimmerman as Chief Financial OfficerThe Board of Next Science Limited appointment and commencement of Marc Zimmerman as Chief Financial Officer.
お知らせ • Jun 29Next Science Limited Commercialising Its Proprietary Xbiotm Suite of ProductsNext Science Limited announced commercialising its proprietary XBIOTM suite of products to reduce the impact of biofilm-based infections in human health, provide the following update. In advance of the forthcoming Appendix 4C and quarterly activity report, Next Science notes continuing improvement in the performance of the business across the quarter-to-date. Next Science advises, that with a few days left in the month, unaudited product sales for 2QFY23 are expected to be above USD 5.6 million. This compares with reported product sales of USD 4.4 million in 1QFY23. As the period for 1HFY23 is about to close, it is clear, that Next Science is on track to substantially exceed product sales in 1HFY22 (USD 5.2 million) and 2HFY22 (USD 6.1 million). This is due to the increased investment in sales and marketing that will continue during the establishment phase of the direct sales model for key products.
お知らせ • Jun 17+ 1 more updateNext Science Limited Announces Executive ChangesNext Science Limited announced the appointment of Harry Thomas Hall, IV (commonly known as I.V.) as its new Managing Director and Chief Executive Officer (CEO). I.V. will commence as CEO on 10 July 2023. To ensure a comprehensive and smooth handover, current CEO, Judith Mitchell, will remain with the company until the end of July. New CEO - Harry Thomas Hall, IV (I.V.): Over the course of 28 years in the global medical device industry, I.V. has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. I.V. joined DePuy Synthes, a subsidiary of Johnson and Johnson in 1997 where he held senior roles including: Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. I.V. was most recently a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes and completed the launch of the first surgical robot developed by JNJ /DePuy Synthes. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V. was responsible for a global portfolio and execution strategy for a USD 3.2 billion platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, I.V. created and sustained personal relationships with well over one hundred key opinion leaders worldwide. I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School. I.V. will be relocating from Pennsylvania to be permanently based in Jacksonville, Florida.
お知らせ • Feb 10+ 4 more updatesNext Science Limited to Report Q2, 2023 Results on Jul 31, 2023Next Science Limited announced that they will report Q2, 2023 results on Jul 31, 2023